NCT01446809View on ClinicalTrials.gov

Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma

NACompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
Stage IIA Adult Soft Tissue SarcomaStage III Adult Soft Tissue SarcomaStage IV Adult Soft Tissue Sarcoma
Interventions
DRUG

Doxorubicin Hydrochloride

Given IV

RADIATION

External Beam Radiation Therapy

Undergo external beam radiation therapy

DRUG

Ifosfamide

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Pazopanib Hydrochloride

Given PO

OTHER

Pharmacological Study

Correlative studies

OTHER

Placebo

Given PO

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT01446809 - Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter